Obesity is a function of biology.
ERX Pharmaceuticals Inc. is developing first-in-class leptin sensitizers for the treatment of obesity and related diseases based on a new understanding of the science of obesity.
ERX is developing first-in-class leptin sensitizers to address unmet needs in the treatment of obesity.
Insensitivity to leptin signaling contributes to a range of metabolic diseases, which may be addressable by leptin sensitizers.
Scientific Advisory Board
ERX is supported by an internationally renowned group of engaged scientific advisors who are experts in the fields of leptin biology and obesity drug discovery.
News & Events
ERX Pharmaceuticals Announces Appointment of Chief Medical Officer Barbara Troupin, MD, MBA and Chief Financial Offer Jonathan Lieber, MBA.